[PERSON]  
6 Orivate Practice, 24128 Bergamo, Italy; m.montemezzi@iberoit  
[PERSON]  
2 Biotechnology Department, Universidade Federal Fluminense, Niteroi 24020-140, Brazil; [EMAIL_ADDRESS] (R.d.L.B. ); [EMAIL_ADDRESS] (G.G.A.) [PERSON]  
2 Biotechnology Department, Universidade Federal Fluminense, Niteroi 24020-140, Brazil; [EMAIL_ADDRESS] (S.C.S. ); [EMAIL_ADDRESS] (M.D.C.-M.)  
[PERSON]  
3 Oral Surgery Department, Universidade Federal Fluminense, Niteroi 24020-140, Brazil; [EMAIL_ADDRESS] (S.C.S. ); [EMAIL_ADDRESS] (M.D.C.-M.)  
[PERSON]  
4 Private Practice, 24128 Bergamo, Italy; m.montemezzi@iberoit  
[PERSON]  
1 Graduate Program, Dentistry School, Universidade Federal Fluminense, Niteroi 24020-140, Brazil; [EMAIL_ADDRESS] (M.D.C.-M.); [EMAIL_ADDRESS] (M.D.C.-M.); [EMAIL_ADDRESS] (K.J.) [PERSON]  
6 Orivate Practice, 24128 Bergamo, Italy; m.montemezzi@iberoit  
R.C.Montemezzi  
2 Biotechnology Department, Universidade Federal Fluminense, Niteroi 24020-140, Brazil; [EMAIL_ADDRESS] (R.d.L.B. ); [EMAIL_ADDRESS] (G.N.G.A.) [PERSON]  
4 Private Practice, 24128 Bergamo, Italy; m.montemezzi@iberoit  
[PERSON]  
1 Graduate Program, Dentistry School, Universidade Federal Fluminense, Niteroi 24020-140, Brazil; [EMAIL_ADDRESS] (M.D.C.-M.); [EMAIL_ADDRESS] (M.D.C.-M.); [EMAIL_ADDRESS] (M.D.C.-M.); [EMAIL_ADDRESS] (K.J.) [PERSON]  
6 Orivate Practice, 24128 Bergamo, Italy; m.montemezzi@iberoit  
[PERSON]  
2 Biotechnology Department, Universidade Federal Fluminense, Niteroi 24020-140, Brazil; [EMAIL_ADDRESS] (R.d.L.B. ); [EMAIL_ADDRESS] (G.N.G.A.) [PERSON]  
4 Private Practice, 24128 Bergamo, Italy; m.montemezzi@iberoit  
[PERSON]  
1 Graduate Program, Dentistry School, Universidade Federal Fluminense, Niteroi 24020-140, Brazil; [EMAIL_ADDRESS] (M.T.S. ); [EMAIL_ADDRESS] (R.C.M.-M.); [EMAIL_ADDRESS] (K.J.) [PERSON]  
4 Private Practice, 24128 Bergamo, Italy; m.montemezzi@iberoit  
[PERSON]  
1 Graduate Program, Dentistry School, Universidade Federal Fluminense, Niteroi 24020-140, Brazil; [PERSON]S] (M.D.C.-M.); [EMAIL_ADDRESS] (M.D.C.  
One of the current strategies is the implantation of the leukocyte-platelet-rich fibrin (L-PRF) immediately after tooth extraction. Prior studies have demonstrated the effectiveness of this autologous biomaterial in reducing postoperative complications in third molars [4; 5]. This second-generation autologous blood-derived biomaterial contains a dense fibrin mesh with increased contents of platelets and leukocytes, as well as increased concentrations of essential growth factors and cytokines that will assist in tissue repair, especially concerning soft tissue healing [6; 7]. Among those, the Transforming Growth Factor Beta (TGF-\(\beta\)), the Platelet-Derived Growth Factor (PDGF), the Vascular Endothelial Growth Factor (VEGF), and the basic Fibroblast Growth Factor (FGF-2) are considered some of the essential mediators produced by leukocytes and platelets in L-PRF membranes. There is strong in vitro evidence of continuous production and release of these mediators by the new autologous biomaterials [7; 8; 9]. Several studies on post-extraction sockets assessing the contribution of L-PRF have shown evaluations that indicated better postoperative and substantial improvements in soft tissue healing and pain reduction, employing tools such as the Landry index for soft tissue repair, and the Visual Analogue Scale (VAS) for pain [4; 5; 10; 11]. These analyses contribute to a qualitative assessment related to the patient's recovery in the postoperative period. It may be supposed that these effects are mainly related to the continuous release of growth factors, previously described by different in vitro studies [9; 12]. However, there is a lack of clinical evidence on the local release of growth factors and cytokines by grafted L-PRF membranes in this model and their correlation with the improvement in pain and tissue healing on the management of third molar extractions.